Don D Sin

Title: Don D Sin: Innovator in Biomarker Detection

Introduction

Don D Sin is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of medical diagnostics, particularly in the detection of biomarkers for chronic obstructive pulmonary disease (COPD) and lung cancer. With a total of 2 patents, his work has the potential to improve patient outcomes and enhance diagnostic accuracy.

Latest Patents

One of Don D Sin's latest patents focuses on methods and systems for detecting plasma protein biomarkers for diagnosing acute exacerbation of COPD. This patent describes compositions and methods that utilize multiple reaction monitoring mass spectrometry (MRM-MS) to quantify protein biomarkers in plasma samples from human subjects. The ability to distinguish acute exacerbations of COPD from stable or convalescent states is a significant advancement in the field.

Another notable patent involves methods for detecting lung cancer and monitoring treatment response. This method includes detecting elevated levels of a CTAP III-related biomarker in biological samples from subjects at risk for developing lung cancer. Additionally, it outlines a method for predicting the risk of lung cancer and monitoring treatment success by comparing biomarker levels over time. These methods incorporate multivariate analysis to evaluate various clinical and demographic risk factors.

Career Highlights

Throughout his career, Don D Sin has worked with esteemed organizations such as the British Columbia Cancer Agency and the University of British Columbia. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include Stephen C-t Lam and John Yee. Their collaborative efforts have further advanced the research and development of innovative diagnostic methods.

Conclusion

Don D Sin's contributions to the field of biomarker detection have the potential to revolutionize the diagnosis and treatment of COPD and lung cancer. His innovative patents and collaborations with leading institutions highlight his commitment to improving healthcare outcomes.